Summary
Sosei Group Corp (Sosei) is a biopharmaceutical company that develops and commercializes drugs. The company’s products include NorLevo, NVA237, QVA149 and SO-1105. Its NorLevo product is an oral emergency contraceptive and SO-1105 is an antifungal agent, administered as a muco-adhesive buccal tablet for the treatment of oropharyngeal candidiasis in immunocompromised patients. Sosei’s NVA237 is a long acting bronchodilator for the treatment of chronic obstructive pulmonary disease. The company provides treatment of Alzheimer's disease, schizophrenia, cancer, migraine, addiction, metabolic disease, and other indications. It operates through various pharmaceutical companies. The company has presence in Japan, Europe and North American pharmaceutical markets. Sosei is headquartered in Tokyo, Japan.
Sosei Group Corp (4565) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the company's operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
'
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Sosei Group Corp, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 6
Sosei Group Corp, Pharmaceuticals & Healthcare Deals By Type, 2010 to YTD 2016 7
Sosei Group Corp, Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 8
Sosei Group Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2010 to YTD 2016 9
Sosei Group Corp, Medical Devices Deals, 2010 to YTD 2016 11
Sosei Group Corp, Pharmaceuticals & Healthcare, Deals Summary, 2010 to YTD 2016 12
Sosei Group Corp, Pharmaceuticals & Healthcare, Deal Details 14
Venture Financing 14
Heptares Therapeutics Raises US$21 Million In Series B Financing 14
Partnerships 16
Jitsubo Enters into Agreement with Heptares Therapeutics 16
Heptares Therapeutics and leadXpro Enter into Agreement 17
Heptares Therapeutics to Form Partnership with Kymab 18
Heptares Therapeutics Enters into Agreement with Pfizer 19
Sosei Plans to Enter into Agreement with Novartis 20
Sosei Enters Into Distribution Agreement With Fujifilm Pharma For SO-1105 21
MorphoSys And Heptares Enter Into Agreement To Develop Antibody Therapeutics Targeting GPCRs 22
Heptares Enters Into Research Agreement With Cubist Pharma For New Medicines Targeting GPCRs 23
ZoBio Enters Into Drug Discovery Agreement With Heptares Therapeutics For Fragment Ligands 24
Activus Pharma Enters Into Co-Development Agreement With CEOLIA Pharma 25
Activus Pharma Enters Into An Agreement With Gifu Pharma University 26
AstraZeneca Enters Into Co-Development Agreement With Heptares 27
Sosei Enters Into Co-Development Agreement With Toa Pharma 29
Heptares Therapeutics Enters Into Drug Discovery Collaboration With Takeda Pharma 30
Licensing Agreements 32
Allergan Enters into Licensing Agreement with Heptares Therapeutics 32
Teva Pharma Enters into Licensing Agreement with Heptares Therapeutics 34
AstraZeneca to Enter into Licensing Agreement with Heptares Therapeutics for HTL-1071 35
Shire Exercises Option To License Adenosine A2A From Heptares Therapeutics 36
BioAlliance Pharma Extends Licensing Agreement With Sosei For Loramyc 38
Equity Offering 39
Sosei Group Raises USD33 Million in Private Placement of Shares 39
Sosei Group to Raise USD7 Million in Private Placement of Shares 41
Sosei Group to Raise USD66 Million in Public Offering of Shares 43
Jitsubo to Raise USD1.7 Million in Private Placement 45
Sosei Announces Private Placement Of Preference Shares For US$3.9 Million 46
Asset Transactions 48
Beijing Tide Pharma Acquires Rights To SD118 From Sosei 48
Acquisition 49
Heptares Therapeutics to Acquire G7 Therapeutics for USD11.83 Million 49
Sosei Acquires Heptares Therapeutics for USD400 Million 50
Sosei to Acquire Stake in Jitsubo for USDUSD1.8 Million 52
Sosei Group Acquires Activus Pharma 53
Sosei Group Corp - Key Competitors 54
Key Employees 55
Locations And Subsidiaries 56
Head Office 56
Other Locations & Subsidiaries 56
Appendix 58
Methodology 58
About GlobalData 58
Contact Us 58
Disclaimer 58
List of Tables
Sosei Group Corp, Pharmaceuticals & Healthcare, Key Facts, 2016 1
Sosei Group Corp, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 6
Sosei Group Corp, Pharmaceuticals & Healthcare Deals By Type, 2010 to YTD 2016 7
Sosei Group Corp, Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 8
Sosei Group Corp, Deals By Therapy Area, 2010 to YTD 2016 9
Sosei Group Corp, Medical Devices Deals, 2010 to YTD 2016 11
Sosei Group Corp, Pharmaceuticals & Healthcare, Deals Summary, 2010 to YTD 2016 12
Heptares Therapeutics Raises US$21 Million In Series B Financing 14
Jitsubo Enters into Agreement with Heptares Therapeutics 16
Heptares Therapeutics and leadXpro Enter into Agreement 17
Heptares Therapeutics to Form Partnership with Kymab 18
Heptares Therapeutics Enters into Agreement with Pfizer 19
Sosei Plans to Enter into Agreement with Novartis 20
Sosei Enters Into Distribution Agreement With Fujifilm Pharma For SO-1105 21
MorphoSys And Heptares Enter Into Agreement To Develop Antibody Therapeutics Targeting GPCRs 22
Heptares Enters Into Research Agreement With Cubist Pharma For New Medicines Targeting GPCRs 23
ZoBio Enters Into Drug Discovery Agreement With Heptares Therapeutics For Fragment Ligands 24
Activus Pharma Enters Into Co-Development Agreement With CEOLIA Pharma 25
Activus Pharma Enters Into An Agreement With Gifu Pharma University 26
AstraZeneca Enters Into Co-Development Agreement With Heptares 27
Sosei Enters Into Co-Development Agreement With Toa Pharma 29
Heptares Therapeutics Enters Into Drug Discovery Collaboration With Takeda Pharma 30
Allergan Enters into Licensing Agreement with Heptares Therapeutics 32
Teva Pharma Enters into Licensing Agreement with Heptares Therapeutics 34
AstraZeneca to Enter into Licensing Agreement with Heptares Therapeutics for HTL-1071 35
Shire Exercises Option To License Adenosine A2A From Heptares Therapeutics 36
BioAlliance Pharma Extends Licensing Agreement With Sosei For Loramyc 38
Sosei Group Raises USD33 Million in Private Placement of Shares 39
Sosei Group to Raise USD7 Million in Private Placement of Shares 41
Sosei Group to Raise USD66 Million in Public Offering of Shares 43
Jitsubo to Raise USD1.7 Million in Private Placement 45
Sosei Announces Private Placement Of Preference Shares For US$3.9 Million 46
Beijing Tide Pharma Acquires Rights To SD118 From Sosei 48
Heptares Therapeutics to Acquire G7 Therapeutics for USD11.83 Million 49
Sosei Acquires Heptares Therapeutics for USD400 Million 50
Sosei to Acquire Stake in Jitsubo for USDUSD1.8 Million 52
Sosei Group Acquires Activus Pharma 53
Sosei Group Corp, Key Competitors 54
Sosei Group Corp, Key Employees 55
Sosei Group Corp, Other Locations 56
Sosei Group Corp, Subsidiaries 56
List of Figures
Sosei Group Corp, Pharmaceuticals & Healthcare, Deals by Type, 2010 to YTD 2016 1
Sosei Group Corp, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 1
Sosei Group Corp, Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 1
Sosei Group Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2010 to YTD 2016 1
Sosei Group Corp, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 6
Sosei Group Corp, Pharmaceuticals & Healthcare, Deals by Type, 2010 to YTD 2016 7
Sosei Group Corp, Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 8
Sosei Group Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2010 to YTD 2016 9
Sosei Group Corp, Medical Devices Deals, 2010 to YTD 2016 11
